Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a hardware-agnostic adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic for use in fracture management. The License and Distribution Agreement is for an initial five-year period, with the option to automatically renew for successive two-year periods at Sanara’s discretion.
OsStic is a disruptive new bio-adhesive bone void filler technology which was granted a Breakthrough Device Designation by FDA in 2023.
The proposed indication statement for OsStic is [a] “structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of periarticular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.”
Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a...
Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a hardware-agnostic adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic for use in fracture management. The License and Distribution Agreement is for an initial five-year period, with the option to automatically renew for successive two-year periods at Sanara’s discretion.
OsStic is a disruptive new bio-adhesive bone void filler technology which was granted a Breakthrough Device Designation by FDA in 2023.
The proposed indication statement for OsStic is [a] “structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of periarticular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.”
Copy to clipboard 
